AVENANCE : efficacité et tolérance en vie réelle d’avelumab en traitement d’entretien de première ligne (1LM) chez les patients atteints d’un carcinome urothélial avancé (aUC) et analyse exploratoire des traitements subséquents

Q4 Medicine Progres en Urologie - FMC Pub Date : 2024-11-01 DOI:10.1016/j.fpurol.2024.07.092

P. Barthélémy , Y. Loriot , C. Thibault , M. Gross-Goupil , J.C. Eymard , E. Voog , C. Abraham , S. Le Moulec , M. Chasseray , A. Gobert , B. Auberger , C. Viala , M. Cabart , E. Kazan , V. Lorgis , W. Hilgers , C. Josse , P. Lambert , M.N. Solbes , A. Fléchon

{"title":"AVENANCE : efficacité et tolérance en vie réelle d’avelumab en traitement d’entretien de première ligne (1LM) chez les patients atteints d’un carcinome urothélial avancé (aUC) et analyse exploratoire des traitements subséquents","authors":"P. Barthélémy , Y. Loriot , C. Thibault , M. Gross-Goupil , J.C. Eymard , E. Voog , C. Abraham , S. Le Moulec , M. Chasseray , A. Gobert , B. Auberger , C. Viala , M. Cabart , E. Kazan , V. Lorgis , W. Hilgers , C. Josse , P. Lambert , M.N. Solbes , A. Fléchon","doi":"10.1016/j.fpurol.2024.07.092","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Avelumab 1LM is the standard treatment for aUC without progression on first-line platinum-based chemotherapy (PBCT) (phase 3 JAVELIN Bladder 100 trial). The AVENANCE real-life study had already confirmed the effectiveness and safety of avelumab 1LM; we report an update of the data and analyzes according to second-line treatments.</div></div><div><h3>Methods</h3><div>The AVENANCE study (<span><span>NCT04822350</span><svg><path></path></svg></span>), non-interventional and ambispective, included patients with aUC without progression on first-line platinum PBCT and treated with avelumab 1LM. The primary endpoint was overall survival (OS).</div></div><div><h3>Results</h3><div>In all, 595 patients were included. With a median follow-up of 26,3 months (0.6–43.7), 125 patients (21.0%) continued treatment with avelumab. The reasons for stopping treatment were: progression (72.5%), adverse event (11.3%), death (9.4%), others (6.8%). In all, 330 patients (55.5 %) received second-line treatment after avelumab: chemotherapy in 244 (73.9%) pts, antibody conjugates (ADC) in 62 (18.8%), and other treatment in 24 (7.3%). The characteristics of patients who received ADC or second-line chemotherapy were generally similar; most had received chemotherapy with carboplatin+gemcitabine in the first line (62.3% vs. 63.6%), presented an ECOG 0/1 (81.6% vs. 82.3%) and had metastatic disease at the beginning of PCBT (96.8% vs. 95.0%).</div><div>Median overall survival from initiation of avelumab 1LM was 21.3 months (95% CI, 17.6–24.6). It was 31.3 months (29.1–NA) in patients who received a 2nd line ADC and 14.4 months (13.2–15.9) for those who received chemotherapy.</div></div><div><h3>Conclusion</h3><div>The new results from AVENANCE confirm the effectiveness of avelumab 1LM in the real-world population. In patients who received second-line treatment (approximately 70 % of patients who discontinued treatment), the current sequence with an ADC after first-line PBCT followed by avelumab 1LM showed encouraging overall survival.</div><div>©2024 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2024 ASCO Genitourinary Cancers Symposium. All rights reserved.</div></div>","PeriodicalId":34947,"journal":{"name":"Progres en Urologie - FMC","volume":"34 7","pages":"Pages S64-S65"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progres en Urologie - FMC","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1761676X24001998","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Avelumab 1LM is the standard treatment for aUC without progression on first-line platinum-based chemotherapy (PBCT) (phase 3 JAVELIN Bladder 100 trial). The AVENANCE real-life study had already confirmed the effectiveness and safety of avelumab 1LM; we report an update of the data and analyzes according to second-line treatments.

Methods

The AVENANCE study (NCT04822350), non-interventional and ambispective, included patients with aUC without progression on first-line platinum PBCT and treated with avelumab 1LM. The primary endpoint was overall survival (OS).

Results

In all, 595 patients were included. With a median follow-up of 26,3 months (0.6–43.7), 125 patients (21.0%) continued treatment with avelumab. The reasons for stopping treatment were: progression (72.5%), adverse event (11.3%), death (9.4%), others (6.8%). In all, 330 patients (55.5 %) received second-line treatment after avelumab: chemotherapy in 244 (73.9%) pts, antibody conjugates (ADC) in 62 (18.8%), and other treatment in 24 (7.3%). The characteristics of patients who received ADC or second-line chemotherapy were generally similar; most had received chemotherapy with carboplatin + gemcitabine in the first line (62.3% vs. 63.6%), presented an ECOG 0/1 (81.6% vs. 82.3%) and had metastatic disease at the beginning of PCBT (96.8% vs. 95.0%).

Median overall survival from initiation of avelumab 1LM was 21.3 months (95% CI, 17.6–24.6). It was 31.3 months (29.1–NA) in patients who received a 2nd line ADC and 14.4 months (13.2–15.9) for those who received chemotherapy.

Conclusion

The new results from AVENANCE confirm the effectiveness of avelumab 1LM in the real-world population. In patients who received second-line treatment (approximately 70 % of patients who discontinued treatment), the current sequence with an ADC after first-line PBCT followed by avelumab 1LM showed encouraging overall survival.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

AVENANCE：阿韦鲁单抗作为晚期尿路上皮癌（aUC）患者一线维持治疗（1LM）的实际疗效和安全性以及后续治疗的探索性分析

引言阿维列单抗1LM是一线铂类化疗（PBCT）（3期JAVELIN膀胱100试验）未进展的膀胱癌标准治疗方法。AVENANCE研究（NCT04822350）是一项非干预性和前瞻性研究，纳入了接受阿维单抗1LM治疗的一线铂类化疗（PBCT）无进展的膀胱癌患者。主要终点是总生存期（OS）。中位随访时间为26.3个月（0.6-43.7个月），125名患者（21.0%）继续接受了阿韦鲁单抗治疗。停止治疗的原因包括：病情进展（72.5%）、不良事件（11.3%）、死亡（9.4%）和其他（6.8%）。共有 330 名患者（55.5%）在接受阿维单抗治疗后接受了二线治疗：244 名患者（73.9%）接受了化疗，62 名患者（18.8%）接受了抗体结合药物（ADC）治疗，24 名患者（7.3%）接受了其他治疗。接受ADC或二线化疗的患者特征基本相似；大多数患者在一线接受过卡铂+吉西他滨化疗（62.3% vs. 63.6%），ECOG 0/1（81.6% vs. 82.3%），在PCBT开始时患有转移性疾病（96.8% vs. 95.0%）。接受二线 ADC 治疗的患者的中位总生存期为 31.3 个月（29.1-NA），接受化疗的患者的中位总生存期为 14.4 个月（13.2-15.9）。在接受二线治疗的患者中（约 70% 的患者停止了治疗），目前在一线 PBCT 后使用 ADC 再使用阿维单抗 1LM 的序列显示出令人鼓舞的总生存期。经许可转载。本摘要已被接受，并曾在 2024 年 ASCO 泌尿生殖系统癌症研讨会上发表。保留所有权利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊